PATIENCE JOHN 4

What Happened
John Patience, Director and Chairman of Biodesix (BDSX), reported a derivative conversion on 2026-03-31 in which 1,361 restricted stock units (RSUs) were converted into 1,361 shares. The filing records the acquisition/conversion of 1,361 shares (derivative) and a simultaneous disposition of 1,361 shares at $0.00; no cash proceeds or market-sale price is shown.

Key Details

• Transaction date: 2026-03-31; Form filed: 2026-04-02 (covers period 2026-03-31). No late filing is indicated.
• Acquired: 1,361 shares via exercise/conversion of a derivative (code M); price listed N/A.
• Disposed: 1,361 shares at $0.00 (derivative disposition); total cash value shown = $0.
• Shares owned after the transaction: not specified in the filing.
• Relevant footnotes:
  • F1: Each RSU represents a contingent right to one share of common stock.
  • F4: These RSUs vest in four substantially equal installments on 3/31, 6/30, 9/30 and 12/31/2026 and have no expiration.
  • F2/F3: Reporting person acts through entities (sole general partner of Patience Enterprises LP and sole trustee of a living trust) and disclaims beneficial ownership except to the extent of pecuniary interest.

Context

• The filing shows a conversion of RSUs to shares (derivative code M). The matching acquisition and $0.00 disposition are recorded but the filing does not explain the reason for the disposition (e.g., tax withholding or transfer).
• Such RSU conversions reflect vesting events rather than open-market purchases or sales and do not by themselves indicate a bullish or bearish view by the insider.